Skip to contentK
Kraig Biocraft Laboratories, Inc.
K
KBLBKraig Biocraft Laboratories, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$1.16M-$1.16MderivedN/M vs Q4 2020 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$516,829N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kraig Biocraft Laboratories, Inc. · CIK 1413119 · Engraved from SEC EDGAR
Operating Cash Flowderived-$395,150N/M Free Cash Flowderived-$412,383— ended Dec 31, 2021 · filed Mar 16, 2022 · 75 d after period end